… with immunomodulatory agents … immunomodulating agents, including neutralizing monoclonal
antibodies, corticosteroids, and other molecules in the management of severe COVID-19, …

… with SARS-CoV and the risk of severe lung injury and thrombosis [60], we think the IVIG
option should be carefully analyzed before its use in severe COVID-19 patients. In addition, the …

… These characteristics are favourable given that duration of use in patients with COVID-19
should be short term. Ruxolitinib, a JAK 1/2 inhibitor, received US Food and Drug …

… antiviral agents with different mechanisms of action have been used for COVID-19 patients
… at summarizing the immunomodulatory drugs administered to treat COVID-19 or alleviate its …

… disruption [2,23]; COVID-19 patients with a previous history of … analysis of COVID-19 effects
reported that patients with a … complications of COVID-19 compared to patients without any …

… of COVID-19 patients, particularly neurological symptoms. We next explain host immune
responses against COVID-19 … , particularly anti-rheumatoid agents and also plasma (with a high …

… of patients treated with or without immunomodulatory drugs. Four hundred and eleven
patients who were diagnosed with COVID-19 … Thirty of these patients had ADs (figure 1). In the …

… of the immunomodulatory drugs used to manage COVID-19. A … the efficacy of the
immunomodulatory agents, including … -purification therapy, in COVID-19 patients. The data were …

… study reported that 20 patients with COVID-19 who received hydroxychloroquine treatment
… immunomodulatory effects may synergize their antiviral effects in the treatment of COVID-19…

… Several repurposed drugs that were documented to be useful in … COVID-19 have been
extensively discussed. Here, we reviewed the roles of immunomodulation as potential COVID-19 …